Gallant is an animal biotechnology company that banks stem cells and develops regenerative medicine, using a pet's natural biology to treat future diseases. While traditional medicine can require daily medication and surgeries that result in difficult side effects, Gallant addresses the root of the symptoms through stem cell therapy. Gallant is the only company that collects cells through a noninvasive method during a dog's routine spay or neuter procedure. They then cryopreserve their stem cells, which would otherwise be thrown away, and are investing millions in developing a pipeline of therapies. At a $595 lifetime fee, Gallant makes it accessible for pet owners to keep their furry friends happy and healthy. Founded by pet tech veteran Aaron Hirschhorn with a team of pioneering researchers in stem cell therapies for pets, Gallant uses the promise of stem cell therapy to keep your dogs enjoying their long runs for the long run.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
10/24/19 | $11,000,000 | Venture |
Bling Capital Bold Capital Maveron Science | undisclosed |